CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
XIENCE Xpedition 2.25 mm stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02513732
NCT02513732N/ACompleted
CompareCT.gov

XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance

Abbott Medical Devices·observational·Posted Aug 3, 2015·Updated May 13, 2021

In Brief

An observational study evaluating XIENCE Xpedition 2.25 mm stent for Ischemic Heart Disease and 3 related conditions. Completed, enrolled 100 participants across 11 sites.

Detailed Summary

The objective of the study is to evaluate the safety and efficacy of XIENCE Xpedition Everolimus-Eluting 2.25mm Stent in real world practice in Japanese hospitals.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Heart Disease, Angina Pectoris, Coronary Artery Disease, Myocardial Ischemia
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 3, 2015
Enrollment StartJul 1, 2014
Primary CompletionSep 1, 2020
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 10.9 years ago

Interventions

XIENCE Xpedition 2.25 mm stentdevice

Patients receiving XIENCE Xpedition 2.25 mm stent